Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England, 2000–13: a secular trend, interrupted time-series analysis. Lancet. 2015; 385:(9974)1219-1228

NIVAS 2019: facing the future in vascular access and infusion therapy

25 July 2019
Volume 28 · Issue 14


The 7th National Infusion and Vascular Access Society (NIVAS) conference was held in Manchester, 12–13 June 2019

Andrew Barton, Chair of NIVAS, opened the conference with a warm welcome and thanks to the conference's main sponsor, B Braun. At this year's conference, the focus was on the future of vascular access and infusion therapy, which was reflected in engaging presentations of the latest technologies in the field, research round-ups, and discussion of how the healthcare workforce will need to evolve to provide the highest quality of care for patients. Attendees were encouraged to tweet about the conference using the hashtag ‘#NIVAS2019’.

In this era of increasing antimicrobial resistance there is a need to develop new antibiotics with novel mechanisms of action. Although the development of new antibiotics has been slow, Dr Ajdukiewicz noted that odilorhabdins are a novel class of natural antibacterial agents produced by enzymes of the nematode-symbiotic bacterium Xenorhabdus nematophila. Odilorhabdins interfere with protein synthesis and are ribosome-targeting. They act against both Gram-positive and Gram-negative bacteria and carbapenemase-producing enterobacteriaceae, and have demonstrated promising efficacy in mouse models.

Register now to continue reading

Thank you for visiting British Journal of Nursing and reading some of our peer-reviewed resources for nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • Unlimited access to the latest news, blogs and video content